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Background: To date there has not been any nationwide age-standardized incidence data 
reported for prostate cancer in Nigeria. We examined and integrated diverse trends in the age-
specific incidence of prostate cancer into a comprehensive trend for Nigeria, and examined 
how best the existing data could generate a countrywide age-standardized incidence rate for 
the disease.
Methods: Data were obtained from studies undertaken between 1970 and 2007 in referral 
hospital-based cancer registries. Records from at least one tertiary hospital in each of the six 
geopolitical zones of Nigeria were examined retrospectively. Data were also reported for the 
rural population in cross-sectional prospective studies. Age-standardized incidence rates and 
the annual incidence of disease were calculated.
Results: Higher incidence rates for prostate cancer during this period were recorded for patients 
aged 60–69 years and 70–79 years, with a lower incidence rate for patients aged younger than 
50 years. An exponential annual incidence rate of disease was observed in the 50–79 year age 
group and peaked at 70–79 years before dropping again at age 80 years. The results showed 
metastasis in more than half of these hospital-based prostate tumors.
Conclusion: Our results suggest that prostate cancer occurs at a relatively young age in   Nigerians 
and that hospital-based registry reports may not appropriately reflect the incidence of the disease in 
Nigeria. A countrywide screening program is urgently needed. Finally, the difference in reported 
stages of disease found in Nigerians and African-Americans versus Caucasians suggests biological 
differences in the prognosis. Nigeria may thus typify one of the ancestral populations that harbor 
inherited genes predisposing African-Americans to high-risk prostate cancer.
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Introduction
Black men of African descent have variously been reported to be at especially high-
risk for developing prostate cancer.1 While the incidence and mortality rates are 
ostensibly higher in African-Americans than Americans of other racial groups,2,3 
  African-Caribbean men are reported to have the highest rate of prostate cancer in the 
world.1 Even worse is the discovery that these African descendants are most likely to 
present at a younger age with more advanced disease, and historically have a poorer 
disease prognosis.4 This supports autopsy reports showing that African-American 
men 20 years or older who died of other causes had a higher incidence and higher 
grade of intraepithelial prostate neoplasia as compared with age-adjusted cohorts 
of Caucasian men.5 In addition, numerous studies of the pathologic characteristics 
of prostate tumors show that African-American patients have higher tumor volumes Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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than Caucasian patients with a similar stage of disease.6 
All these   observations   suggest that biological differences 
in   tumorigenesis may be a factor in the course of disease 
among races.6 Indeed, numerous studies have character-
ized several genes, the expression patterns and variants7,8 
of which determine the tumoral heterogeneity9 which 
characterizes the disparity in incidence and aggressiveness 
of disease found among African-American and Caucasian 
patients.10,11 Currently, there is a good deal of literature claim-
ing that lifestyle factors impact the risk of prostate cancer 
in   African-  Americans. Accordingly, the wide variations 
in cancer incidence among populations living in different 
regions of the world echo the suggestion that the majority of 
malignant tumors are triggered by environmental factors.12
Epidemiological and population studies indicate that life-
style variables seldom account for the disparities in prostate 
cancer risk among different groups,13 but rather suggest that 
interaction of specific genetic and lifestyle factors critically 
predisposes populations to most cancers.14–16 Regrettably, 
there has been no consensus as to whether the higher inci-
dence of prostate cancer or the disturbing two-fold higher 
mortality rate from this disease among African-Americans17 
is driven by “behavior”, “ biology”, or both. Historically, all 
individuals in this diaspora are people of African descent, 
and it is logical that men of African ancestry share common 
genetic or familial factors that may increase their vulner-
ability to prostate cancer.18 Although the contribution of 
hereditary factors in cancer has been considered minor, 
the estimated effects of genetic factors for five tumors vary 
considerably, with the highest effect observed in prostate 
cancer.16 This has been corroborated by recent studies 
showing that African-American patients with gender-specific 
malignancies like prostate cancer have worse survival than 
white patients, despite controlling for prognostic, treatment, 
and socioeconomic factors.19 This has led to the conclusion 
that unrecognized interactions of host biological, hormonal, 
and/or inherited factors may contribute to differential sur-
vival outcomes by race in gender-specific malignancies 
like prostate cancer. The mechanism of inherited genetic 
predisposition, which is responsible for the varied intereth-
nic response to environmental factors, could be obscured 
in the genetic framework of ancestral populations in the 
African diaspora. Mining of such data could reveal trends 
in the incidence of prostate cancer in these populations. 
Consistency in incidence trends in such ancestral populations 
as the African diaspora could encourage the search for an 
inherited genetic predisposition that responds to behavioral 
triggers for the disease. In this paper, we present emergent 
Figure 1 Geopolitical map of Nigeria.
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Table 1 Teaching hospitals and cancer registries with published data and information on prostate cancer incidence in the geopolitical 
zones of Nigeria
Geopolitical zones/population#  
(% of national population)
Teaching/tertiary hospital*/** 
(other hospitals in the zone)
Core and peripheral  
states
South-South
21,014,655 (15.01%)
University of Calabar Teaching Hospital, Calabar; University of Benin  
Teaching Hospital, Benin; University of Uyo Teaching Hospital, Uyo;  
Niger Delta University Teaching Hospital. Yenogoa; University of Port  
Harcourt Teaching Hospital, Port Harcourt; Delta State University  
Teaching Hospital, Oghara; other hospitals (n = 111)
Akwa-Ibom, Bayelsa,  
Cross River Delta, Edo  
and Rivers
South-East
16,381,729 (11.7%)
University of Nigeria Teaching Hospital, Enugu; Abia State University 
Teaching Hospital, Aba; Ebonyi State University Teaching Hospital,  
Abakaliki; Imo State University Teaching Hospital, Owerri; Enugu State  
University Teaching Hospital, Enugu; Nnamdi Azikiwe University  
Teaching Hospital, Nnewi; other hospitals (n = 120)
Abia, Anambra, Ebonyi,  
Enugu, Imo
South-west
27,581,992 (19.65%)
University College Hospital, Ibadan; Lagos University Teaching Hospital,  
Lagos; University Teaching Hospital, Ado Ekiti; Olabisi Onabanjo University  
Teaching Hospital, Sagamu; Lagos State University, Teaching Hospital,  
Ikeja; Obafemi Awolowo University Teaching Hospital, Ile-Ife; Ladoke  
Akintola University Teaching Hospital, Osogbo; other hospitals (n = 412)
Ekiti, Lagos, Ogun, Ondo,  
Osun, Oyo
North-East
18,971,965 (13.55%)
University of Maiduguri Teaching Hospital, Maiduguri; Abubakar Tafawa  
Balewa University Teaching Hospital, Bauchi; other hospitals (n = 84)
Adamawa, Bauchi, Borno,  
Gombe, Taraba, Yobe
North-Central 
20,266,257 (13.46%)
University of Ilorin Teaching Hospital, University of Abuja Teaching  
Hospital, Abuja; Benue State University Teaching Hospital, Makurdi,  
Jos University Teaching Hospital; other hospitals (n = 175)
Benue, Abuja (Federal Capital   
Territory), Kogi, Kwara,  
Nasarawa, Niger, Plateau
North-west
35,786,998 (25.56%)
Ahmadu Bello University Teaching Hospital, Zaria; Aminu Kano Teaching 
Hospital, Kano; Usmanu Danfodiyo University Teaching Hospital, Sokoto;  
other hospitals (n = 80)
Kaduna, Katsina, Kano, Kebbi,   
Sokoto, Jigawa, Zamfara
Notes: *Other tertiary, secondary hospitals, or health facilities (public, mission, and private) not enumerated here exist in all zones, but had no published data or information 
for this study. Core states where listed hospitals are located are italicized; **Other hospitals include federal medical centers, specialist hospitals, mission hospitals, private 
hospitals, and general hospitals; #Population figures based on the provisional National Population of Nigeria March 2006 census results.
trends in the reported incidence of prostate cancer in modern 
day Nigeria, a country that accounts for a highly significant 
proportion of the African diaspora.20 Correlation in features 
of the disease in these two populations could guide the search 
for the biology of the disease in these populations.
Methods
Design and study population
We grouped together prospective and retrospective data 
previously obtained from histologic and clinical records at 
the tertiary referral or university teaching hospitals serving 
the six Nigerian geopolitical zones (Figure 1), each of which 
covers a core state and several peripheral states. The data 
provided by the teaching hospitals in each of the geopolitical 
zones and their peripheral states are shown in Table 1. Our 
study population was broadened because we examined data 
from two or more such tertiary health institutions in a zone. 
Because our data embraced all of the geopolitical zones in 
Nigeria, the information it provides may constitute the most 
extensive hospital-based prostate cancer incidence report for 
Nigeria so far. Nonetheless, the present data compensate for 
the lack of satisfactory prostate cancer incidence data that 
ought to be coordinated and collated by the Ibadan University 
College Hospital (UCH) National Headquarters for Cancer 
Registries in Nigeria. Such data ought to be generated by 
population-based screening for prostate and other cancers 
in the presently existing university teaching hospital-based 
registries at Maiduguri, Zaria, Jos, Kano, Ilorin, Calabar, 
Enugu, Lagos, and Ife-Ijesha. The data presented in this 
report were retrieved by researchers from these teaching 
hospital-based registries, except for the Usman Danfodiyo 
UCH records, which were obtained from a cancer patient 
register in the department of histopathology. The histology 
and cytology specimens21,22 used for some of these studies 
were obtained from tertiary, secondary, and private hospitals 
located close to the core tertiary hospital and the surrounding 
peripheral states, towns, and villages23 within that particular 
geopolitical zone. In a few surveys of prostate cancer risk 
from a seldom-screened cohort of the rural population, 
participants were invited for a health survey after alerting 
them to the procedures involved, including a blood test 
and digital rectal examination (DRE) by a local nurse.24 
In many of the retrospective studies, information on the age 
of patients at presentation,21,25–27 histopathological grading, 
mode of presentation, clinical and biochemical response to 
chemotherapy, their relative frequencies,28 and the level of Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
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prevailing tumor biomarkers were obtained from patient 
files.29–31 In prospective studies, data were obtained from 
patients presenting with histologically diagnosed carcinoma 
of the prostate during the study period.32 Again, in the pro-
spective studies, various patient information was documented 
including, but not limited to, prevailing biomarker levels such 
as serum acid phosphatase, DRE, blood electrolyte profile, 
prostate biopsy, transabdominal ultrasonography, and a 
survey of the skeleton.32,33 In some of the more recent cases, 
detection of prostate cancer by prostate-specific antigen 
(PSA) was preceded by DRE. In most cases, the diagnosis 
was made on the basis of DRE, an ultrasound scan (which 
when combined with artificial neural network classification 
tools enabled encouraging differentiation between cancerous 
and noncancerous tissue),34 and confirmed by Tru-Cut (UK 
Medical Limited, Sheffield, UK) prostatic biopsy.21 In certain 
cases too, the clinical staging of the disease was determined 
using the tumor, node, metastasis (TNM) system at the time 
of DRE.29 In others, the prostate was carefully assessed for 
size, hardness, nodularity fixation, and discomfort.33 Staff 
at the registries was centrally trained through programs 
run by the National Headquarters for Cancer Registries in 
Nigeria and delivered as instructed data items abstracted 
from pathology reports, medical charts, and questionnaires 
to treating physicians in order to obtain complete data on 
therapies. To avoid duplication, all retrieved records were 
reported to have been double-checked by name and matched 
with hospital numbers. Cases presented by the reports ranged 
from 125 to 4686, where large number of cases represented 
retrospective studies of all malignant diseases studied over a 
longer period. Age-standardized rates were calculated using 
Nigerian census figures for the appropriate study periods. 
The mean sample size for assessment of prostate tumors and 
benign prostatic hyperplasia was 327 ± 280.12. Studies were 
variously approved by the research and ethics committees of 
the tertiary health institutions involved.24
Statistical analysis
Many statistical measures have been developed to compare 
the incidence rates of particular cancers for different age 
groups in two or more populations. A long list of references 
and sources of information indicate extensive discussion on 
the subject.35–37 We used some of the accepted standards to 
calculate different statistics for estimating and comparing the 
incidence rate of prostate cancer for different age groups in 
different zones of Nigeria. In order to delineate the different 
age structures of the populations in each geopolitical region, 
the direct method of standardization was applied to the data 
shown in Tables 2 and 3. The primary statistics in the direct 
method are age-specific rates, ai,38 calculated as the incidence 
rate per 100,000 by the formula:
  a
d
y
i
i
i
= * , 100 000
where di is the number of cases in the ith age group and yi is the 
person-years of observation in the ith age group. Person-years 
are the population at risk and the time it contributes. The above 
formula indicates the age incidence rate of prostate cancer 
per 100,000 of each age group for the population covered 
by a particular hospital calculated by dividing the number of 
new prostate cancer cases by the number of person-years at 
risk for every age group and multiplying that by 100,000.38 
Person-years at risk were found by multiplying the number 
of males in different age groups in the Nigerian population 
(obtained from population pyramids of Nigeria)39 during the 
observation period. Then, in order to compare the age-specific 
Table 2 Hospital-based age structure of patients with prostate cancer within the various zones of Nigeria (Pre-PSA era 1970–1999)
Age, 
years
Geopolitical zones
SS29+ 
n (%)
SE50 
n (%)
SW26+ 
n (%)
NE 
n (%)
NC56 
n (%)
NW31 
n (%)
,50 3 (2) 19 (16) 18 (6) Data N/A 4 (2.7) 4 (4)
50–59 30 (21) 40 (33) 57 (18) 14 (9.5) 19 (20)
60–69 44 (30) 49 (40) 99 (32) 51 (34.7) 41 (43)
70–79 58 (40) 13 (11) 97 (31) 43 (29.3) 29 (31)
$80 10 (7) 39 (13) 23 (15.6) 2 (2)
Unspecified 12 (8.2)
Period (1984–1994) (1970–1980) (1990–1996) (1979–1996) (1993–1999)
Biomarkers Pre-PSA Pre-PSA Pre-PSA Pre-PSA Pre-PSA
Total 145 (100) 121 (100) 310 (100) 147* (100) 95 (100)
Notes: Figures in superscript denote citation references. +Figures derived from histograms; *Denote mistaken data count in original manuscript; Data N/A denote Journal 
article was not easily accessed online or in most libraries.
Abbreviations: PSA, prostate-specific antigen; SS, South-South; SE, South-East; SW, South-West; NE, North-East; NC, North-Central; NW, North-West.Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
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Table 3 Age structure of patients with prostate cancer within various zones in Nigeria (PSA era 1991–2007)
Age, 
years
Geopolitical zones
SS1
24 
n (%)
SS2
61 
n (%)
SE SW2
43,# 
n (%)
NE 
n (%)
NC 
n (%)
NW25 
n (%)
,50 na na Data N/A 8 (4.2) Data N/A Data N/A 5 (14)
50–59 3 (21)* 8 (17.8) 44 (23.3) 4 (11)
60–69 3 (21) 12 (26.7) 68 (36) 10 (27)
70–79 4 (29) 25 (55.6)** 57 (30.2) 14 (38)
$80 4 (29) 12 (6.3) 4 (11)
Period (2003) (2001–2004) (1991–2007) (2000–2002)
Biomarkers PSA era PSA era PSA era PSA era
Total 14 (100) 45 (100) 189 (100) 37 (100)
Notes: Figures in superscripts denote citation references. +Figures derived from men with PSA level $ 4.0 in rural prospective cross-section studies of prostate cancer 
incidence. #Figures derived from histograms. Na indicates cases were not available for that particular age-group; *Indicates data that include patients in the age group ,60 years. 
**Indicates that data include all patients in the age group $ 70 years. Data N/A denote journal article was not easily accessed online or in most libraries.
Abbreviations: PSA, prostate-specific antigen; SS, South-South; SE, South-East; SW, South-West; NE, North-East; NC, North-Central; NW, North-West.
rates between different age groups within a geopolitical region 
and between geopolitical regions, the observed age-specific 
rates were standardized against the reference population, 
ie, the standard world population for each age group. This 
became the hypothetical value for age-specific rates, which 
would have occurred in the ith age class of the reference 
population. Standardization in the ith age class was found by 
the product aiwi, where wi was the reference population for 
the age group i. The total of all the incidence rates (Σ ai, wi) 
gave the age-standardized incidence rate per 100,000 world 
population for prostate cancer among Nigerians. Finally, the 
most important statistic is the mean annual age-standardized 
incidence rate (ASR) of prostate cancer per 100,000 of males 
in Nigeria, and is calculated as:
  ASR
aw
w
ii
i
=
Σ
Σ
Variance is given by the formula:
  VarA SR
aw a
y
w
ii
i
i
i
()
()
()
=
−
Σ
Σ
2
2
100000
And the 95% confidence interval by:
  (. () ,. () ASRV ar ASRA SR VarA SR −∗ +∗ 19 61 96
For data in Tables 4 and 5, the ASR, the standard error 
() SE Var(ASR) = , and 95% confidence interval were 
  calculated for each region and provided summary compari-
son statistics. Two more statistics were also included in the 
data, ie, firstly, the crude (all-ages) rates per 100,000 person-
years for all regions, which were used to amplify the effect 
of age and the geopolitical zone on the average incidence 
rate of prostate cancer and, secondly, the cumulative rate 
and the corresponding measure for cumulative risk. The 
cumulative rate was the total Σ ai, ti where it was the obser-
vation period of it age class of each geopolitical zone, and 
cumulative risk was the percentage risk a Nigerian residing 
in one of the geopolitical regions could have of developing 
prostate cancer (if no other causes of death were present). 
Cumulative risk was calculated from cumulative rate using 
the relationship:
  100 1
40
−− 
 

 

 

  Expc umulative
rate
100
Results
Demographic information from the registries was divided 
into the pre-PSA and PSA eras. The “pre-PSA era” comprised 
data recorded between 1970 and 1999, and only included 
reports in the 1990s that did not detect prostate cancer by 
any of the PSA assays. The “PSA era” encompassed cases 
that were detected between 1991 and 2007, and considered 
mostly prostate cancer cases that were detected by any of 
the PSA assays. This classification considered the late 1980s 
as the period when PSA became the diagnostic tool for 
prostate cancer in the Western world, while its countrywide 
application in Nigeria was only very recent. Data from the 
pre-PSA era comprised various prospective and retrospective 
hospital-based records of prostate cancer across the geopo-
litical zones, except for the inaccessible figures from the 
North-East (NE), arranged according to age and incidence 
(Table 2). Representative data obtained from countrywide 
registries revealed that approximately 98% of the prostate 
cancer cases were adenocarcinoma.23,29,30,50 Nonetheless, 
two patients (1.4% and 1.1%) presented with squamous cell Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
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Table 6 Age distribution of prostate-specific antigen values from some zones in Nigeria
Age, years PSA (ng/mL)
SS24,# n (%) Mean (median) SS68 n% Mean ± SD SS69/SE** n% Mean ± SD
,50 56 (37.1) 1.17 (0.60) 522 (39.4) 2.15 ± 1.62 N/A
50–59 34 (22.5) 1.57 (0.55) 416 (31.4) 3.03 ± 1.81 6 (12.8) 7.3 ± 2.7
60–69 32 (21.2) 2.05 (0.90) 245 (18.5) 4.85 ± 2.74 18 (38.3) 9.3 ± 3.0
70–79 16 (10.6) 5.69 (1.25) 105 (7.9) 6.32 ± 3.06 21 (44.7) 11.9 ± 4.0
$80 8 (5.3) 13.75 (4.45) 37 (2.8) 9.74 ± 4.51 2 (4.2) 18.0 ± 8.0
Period (2003) 2007–2010 2002–2003
Total 146 1325 47*
Notes: *Mean PSA values reported here are from 47 prostate cancer patients. PSA for 71 age-matched control subjects are, respectively, 2.5 ± 0.9, 2.3 ± 0.5, 1.9 ± 0.7, and 
2.1 ± 0.7 ng/mL; **Study subjects overlapped two geopolitical zones, ie, SS and SE; #Data reported as mean and median.
Abbreviations: SS, South-South; SE, South-East; PSA, prostate-specific antigen; SD, standard deviation; SE, standard error of the mean.
carcinoma or adenosquamous carcinoma in the South-South 
(SS) and South-West (SW), respectively.29,43 However, the 
report from the NE indicated that most of these patients 
presented with symptoms similar to those of benign pros-
tatic hyperplasia.21 Apart from specifying the differentiated 
types of adenocarcinomas, identification of specific histo-
logic subtypes as, eg, small cell, ductal, and mucinous, was 
not reported. Data from these zonal registries showed that 
the highest incidence rate for prostate cancer was among 
patients in the 60–69 year and 70–79 year age brackets. In 
contrast, the age cohorts below 59 years presented with the 
lowest incidence of prostate cancer in all the zones during 
the study period. Despite the sparse tertiary hospital-based 
incidence data obtained for each geographic population, we 
computed a crude and age-standardized incidence rate of 
prostate cancer for the different age groups (Tables 4 and 5). 
Furthermore, even in the PSA era, we observed a trend similar 
to the age-specific incidence of disease found in the pre-PSA 
data (Table 3). However, in most data from the PSA era, age-
specific incidence rates of disease in cohorts below 59 years 
were surprisingly high, especially in the SS1, SW2, and 
North-West (NW) zones. The detection of some concealed 
cases of prostate cancer in the SS and a section of the SE 
by PSA tests is presented in Tables 6 and 7. Distribution of 
PSA values according to patient age (Table 6) shows that the 
mean values for prospective, cross-sectional, and prospec-
tive hospital-based studies ranged between 1.17 ng/mL and 
18.0 ng/mL. Each of these studies also confirmed that PSA 
values are age-dependent. Furthermore, the complementar-
ity of PSA and DRE in predicting prostate cancer was also 
established in these populations (Table 7). Here, between 
41.4% and 46.15% of prostatic cases detected by a PSA 
cutoff $ 4.0 were confirmed as symptomatic and palpable 
by DRE tests. In contrast, between 23.08% and 96% of pro-
static cases detected by a PSA cutoff $ 4.0 were shown to 
be enlarged but asymptomatic by DRE. Irreconcilable data 
from the zones for the detection of prostate cancer by PSA 
measurements were omitted.
Figures 2 and 3, respectively, show our calculated crude 
pre-PSA and PSA era annual incidence rates for prostate 
cancer per 100,000 of defined age groups for the estimated 
census populations serving the specific zonal tertiary health 
institutions. These curves show an exponential annual inci-
dence rate of disease in the age group 50–79 years, with a 
peak annual incidence at 70–79 years in most cases except 
in the cross-sectional studies from SS1 (Figure 2) where the 
incidence rate reached a peak at $80 years. In both eras, the 
calculated annual incidence rate for all zonal populations 
dropped beyond the age of 79 years, except for the reported 
rise in incidence in SS1. Overall, the annual incidence rate 
recorded for the SW geopolitical zone in both eras was dra-
matically different from that in the other zones. The crude 
rate and the average annual age-standardized rate for prostate 
cancer by region in the period before and during the PSA 
era are shown in Tables 4 and 5, respectively. Based on these 
data, further cumulative risk (%) ranking conferred the SW 
and North-Central (NC) zones with the highest crude and 
age-standardized rates in the pre-PSA era (Table 4). This 
cumulative risk ranking was surpassed by values obtained 
from the SS zone during the PSA era (Table 5).
The few reports that described the extent of prostate can-
cer spread were based on TNM classification (Table 8) and 
Whitmore-Jewett stages (Table 9). From the TNM classifica-
tion, 81.5% of the tumors in hospital-based cases from the 
SE zone had spread through the prostatic capsule, as opposed 
to 19.3% of such cases reported in the SS zone. Worse still, 
within the SS zone, most patients reporting to hospitals had 
tumors that had invaded nearby structures, as observed by T4 
clinical staging (62.1%). Approximately one-third or more of 
the patients whose tumors were scored by Whitmore-Jewett Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
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Table 7 Distribution of percentage of men with elevated PSA and their prostate cancer status
Region PSA (ng/mL) Prostate status by DRE  
Normal Enlarged 
 
Enlarged nodular
No symptoms n (%) With symptoms n (%) Cancer suspected n (%) Confirmed n (%)
SS24 $4.0 3 (23.08) 3 (23.08) 6 (46.15) 1 (7.69)
SS68 $4.0 58# (59) N/A 41 (41.41)* 41 (41.41)
SS70 $4.0 162 (57.7)  96 (34.2) N/A N/A@
Notes: #Men in this category had raised PSA with prostate enlargement, prostatitis, or benign prostatic hyperplasia; *All men having enlarged prostate with symptoms were 
confirmed with prostate cancer; @Data did not explain status of enlarged prostates.
Abbreviations: SS, South-South; N/A, cases not available; PSA, prostate-specific antigen; DRE, digital rectal examination.
staging presented with prostate tumors extending through the 
capsule at the time of reporting to hospital (28.6%, 42.9%, 
and 27.2% reported in the SE, SW1, and SW2, respectively). 
Expectedly, Whitmore-Jewett staging also showed that not 
less than half of the patients seen in tertiary hospitals in all 
the reported zones presented with tumors that had spread to 
other organs (59.7%, 51.3%, and 59.2% in the SE, SW1 and 
SW2, respectively, Table 9). This trend is thus similar to the 
picture presented by previous grading of patients on the TNM 
classification. Finally, from the histologic subtypes (Table 10), 
20%–49.5% of tumors recorded in the northern zones were 
considered to be high grade or poorly differentiated. Again, 
using this scoring system, 51%–80% of tumors were   classified 
as generally low grade tumors. Generally, in this case, a little 
less than a third or more of the tumors seen were defined as 
high grade, which is close to the proportion seen for TNM 
and Whitmore-Jewett staging reported earlier.
Discussion
No study to date has evaluated the nationwide annual inci-
dence rate and clinical characteristics of prostate cancer 
in Nigeria. In the present study, data from all university 
teaching hospital-based registries in the geopolitical zones 
of Nigeria except for the NE zone showed that patients aged 
60–69 years and 70–79 years had the highest rate of prostate 
cancer. The only available information on prostate cancer 
demographics21 from the NE zone is a PubMed abstract 
indicating that the majority (56%) of affected patients were 
65 years of age or younger. The report also showed that most 
patients in this group presented with symptoms similar to 
benign prostatic hyperplasia. However, details such as his-
tologic tumor grade and age distribution of patients were 
inaccessible for our study. In addition, the high incidence of 
the disease observed in men aged 60 years and older in all 
geopolitical zones of Nigeria is consistent with the obser-
vation that age-specific incidence rates of prostate cancer 
rise steadily with advancing age worldwide.41 These results 
corroborate those of previous studies identifying the 65–70 
year age group in males from Ibadan and Washington, DC, 
as presenting with the peak incidence of carcinoma of the 
prostate.42 The average peak incidence according to age in 
most of the reports predated the seventh decade of life. This 
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is slightly lower than the mid years of the seventh decade 
reported for Caucasians in Europe and the US,43–45 leading 
us to suspect that prostate cancer occurs at a relatively 
younger age among Nigerians.43 Equally, the available data 
from Nigeria show lower prostate cancer incidence rates 
(2%–16% and 4.2%–37.1% for the pre-PSA and post-PSA 
era, respectively) for patients aged younger than 50 years. 
The observation that a subset of patients with prostate cancer 
present at a younger age is consistent with the universal pat-
tern whereby only few prostate cancer cases in the population 
have a genetic predisposition leading to early onset of the dis-
ease.29,46,47 Close scrutiny of the age distribution of prostate 
cancer cases from the zonal registries in Nigeria revealed the   
disease burden in a number of patients whose ages ranged 
from (slightly less than) 50 years and above. This justifies the 
sensitivity of PSA as a tumor marker, and also demonstrates 
its benefit in detecting previously undiagnosed cases that 
might only present in old age. Data obtained from prospec-
tive cross-sectional studies on the age distribution of prostate 
cancer in the PSA era reveal a narrowing of the incidence of 
the disease from the age group 60–79 years to that .50 years 
or 50–59 years.24 This finding strengthens the evidence for an 
earlier age of disease prevalence in the Nigerian population, 
but weakens the argument for use of hospital-based registry 
reports to demonstrate the incidence of prostate cancer in 
Nigeria. Given that hospital-based incidence records do not 
reflect the true nature of the disease in Nigeria, the observa-
tion of advanced disease in these patients points strongly to 
the need for cross-sectional or population-based surveys that 
would uncover latent and asymptomatic cases, especially in 
the middle-aged population. Currently, the influence of the 
environment, including dietary risk factors, in early onset of 
disease is being emphasized.48,49 Nonetheless, the reliability 
and significance of the different ages quoted in these data 
have previously been questioned considering the literacy 
level of the parents of some of these patients and unreliability 
of some of their birth records.50 This concern seems genuine, 
considering that reliable birth recording was not mandatory 
in some remote parts of the country until 50 years ago.
Indeed, the sources of data for this report made calcula-
tion of a nationwide age-standardized incidence of prostate 
cancer almost impossible. A reason for this is that the exact 
population sizes encompassed by the different tertiary hos-
pitals within the geopolitical zones are indeterminate. This 
is associated with the imprecise and overlapping character 
of the surrounding states and towns served by these hospi-
tals. In such cases, census figures for calculating persons at 
risk in a defined area are based on guesswork. These figures 
could be so large as to reduce the expected age standardized 
incidence rates of the disease following a measure of the quo-
tient obtained from the number of reported cases versus the 
product of the standard world population of persons at risk. 
Furthermore, the futility of calculating an age-standardized 
incidence rate is also associated with the reliance on hospital-
based data in a society with little health education, poor health 
care, and inadequate screening programs. Overall, inad-
equacy in health education and the lack of effective screening 
programs could be a factor in the presentation of very severe 
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cases in hospitals, therefore skewing the actual prevalence 
of the disease against the age-standardized incidence rates. 
The overall impact of this shortcoming could be inaccuracy 
of locally obtained hospital-based data on age-standardized 
incidence rates when compared with data obtained around 
the world. Notwithstanding these shortcomings, the crude 
and average annual age-standardized incidence rates for 
prostate cancer in all the zones were calculated to draw 
attention to the exact nationwide character of the disease. 
The pre-PSA data for the SW and NC zones showed the 
highest crude and age-standardized rates, but were surpassed 
by the SS zonal studies in the PSA period. In addition to the 
disparity in health care that occasionally causes regional 
differences in the incidence of the disease, other factors 
like lower screening rates, cultural factors, and less aggres-
sive therapy, could account for the differences observed in 
the regional crude and age-standardized rates obtained in 
this study. The reliability of data from such settings should 
be investigated in either a series of cross-sectional studies 
or, better still, a countrywide population-based screening   
program.
It is to be expected that the age-specific incidence of 
prostate cancer among Nigerian men aged 59 years or 
younger increased during the PSA period as opposed to 
the pre-PSA era. A reason for this, as shown by reports 
from the SS1,24 SW2,43 and NW25 zones is adherence to 
existing methods for diagnosis of prostate cancer and risk 
assessment. Annual DRE and measurement of serum PSA 
are currently recommended beginning at age 50 years and 
advocated to start at age 45 years in those whose first-degree 
relatives had the disease.51,52 The increase in the number of 
diagnosed prostate cancer cases among Nigerian age cohorts 
that previously showed moderate cases confirm that, most 
men are now diagnosed with the disease in its early stages 
(localized disease) because of the detection of elevated or 
rising serum PSA detected during screening.51 A parallel may 
be drawn with the younger age at onset of prostate cancer 
among Nigerian and African-American patients as opposed 
to Caucasians.53 Reasons for such differences have been 
suggested to be genetic, pathologic, molecular, and/or socio-
economic.53 Nevertheless, age is still universally accepted as 
an important risk factor for prostate cancer, which is rarely 
seen in men younger than 40 years of age. The increased use 
of PSA as a screening test for Nigerian men, in addition to 
the increase in cross-sectional or population-based surveys, 
has led to detection of a significant number of latent cases, 
as has been observed in other places, which may potentially 
lead to a dramatic reduction in the number of patients with 
metastatic disease at the time of diagnosis.51
The rapidity with which the calculated annual incidence 
of prostate cancer per 100,000 for defined age groups in the 
corresponding zonal populations progressed beyond 50 years 
of age is similar to previously reported US data on age-specific 
incidence curves.54 However, this upsurge in incidence of 
prostate cancer from 50 years of age onwards contrasts with 
the steady rise observed in China and the Middle East.55 The 
Table 8 Clinical stages of prostate cancer reported in different 
zones of Nigeria
Geopolitical zones
Clinical stages (TNM) SS29 n (%) SE2
60 n (%)
T1 8 (5.5) –
T2 13 (9.0) 5* (18.5)
T3 28 (19.3) 22 (81.5)
T4 90 (62.1) –
Not stated 6 (4.1)
Period (1984–1999) (1993–1998)
Total 145 (100) 27 (100)
Note: Figures in superscript denote citation references. *Indicates that tumor stage 
was not specified as T1 or T2, and is only referred to as early disease.
Abbreviations: SS, South-South; SE, South-East; TNM, tumor, node, metastasis. 
Table 9 Clinical stages of prostate cancer reported in different 
zones of Nigeria
Clinical 
stages 
(Whitmore-Jewett)
Geopolitical zones
SE32,* 
no. (%)
SW1
43 
no. (%)
SW2
33 
no. (%)
A 21 (2.5) 11 (5.8) 3 (2.4)
B 78 (9.2) – 14 (11.2)
C 242 (28.6) 81 (42.9) 34 (27.2)
D 506 (59.7) 97 (51.3) 74 (59.2)
Period (1989–1998) (1991–2007) (1988–1993)
Total 847 (100) 189 (100) 125 (100)
Notes: Figures in superscript denote citation references. *Indicate data are from 
combined reports of carcinoma of the prostate after previous prostatectomy for 
BPH and cases with carcinoma in intact prostate.
Abbreviations: SS, South-South; Sw, South-west.
Table 10 Histological scoring of prostate cancer reported in 
different zones of Nigeria
Scheme of histologic  
features
Geopolitical zones
NC56 
n (%)
NW1 25 
n (%)
NW2
31 
n (%)
well differentiated 79 (67) 36 (37.9)
Moderately differentiated 15 (13) 27* (73) 12 (12.6)
Poorly differentiated 24 (20) 10 (27) 47 (49.5)
Period (2001–2004) (2000–2002) (1993–1998)
Total 118 (100) 37 (100) 95 (100)
Note:  Figures  in  superscript  denote  citation  references.  *Indicates  that  tumor 
stage  was  not  specified  and  figures  include  well  differentiated  and  moderately 
differentiated types.
Abbreviations: NC, North-Central; Nw, North-west.Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
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upsurge in incidence after 50 years of age in the US had been 
attributed to its increased detection in these age cohorts.55 
Also, higher life expectancy in the US could have caused the 
sharp rise in incidence rate in men aged over 50 years, because 
most men in the US live long enough to develop this “disease 
of the elderly”. In contrast, the sharp rise in prostate cancer 
among Nigerian men aged 50–79 years could be attributed to 
the survival of these men into the period of life when prostate 
cancer manifests clinically and is detected. The peak annual 
incidence at 70–79 years accounted for a third of all hospital-
based prostate cancer cases observed in Nigeria. There may 
be a number of reasons for the decline in annual incidence 
rate for men aged 80 years and older in all the zones. To begin 
with, life expectancy in Nigeria is far less than 80 years, and 
as such, very few men live to this age,56 thus skewing the 
number of hospital cases. This could be compounded by the 
fact that 50%–81% of Nigerian patients present with clinically 
obvious and advanced disease,29,56 ie, higher rates of palpable 
disease with adverse prognostic features. The influence of life 
expectancy on the incidence of prostate cancer in the elderly 
is well known from data generated in the Western world.57,58 
Again, the decline in incidence rate after 80 years of age in 
Nigeria could relate directly to the low socioeconomic status 
of the majority of the population, poor access to health care, 
and poor health awareness nationwide. In such a scenario, 
these men are unlikely to undergo prostate cancer screening, 
and could have impalpable and undetectable prostate cancer, 
which might only be detected as an incidental finding or on 
biopsy. Lastly, the dramatic deviation in annual incidence 
of prostate cancer recorded in the SW26,43 in favor of much 
higher incidence rates as compared with other geopolitical 
zones could be explained by the historic location of the cancer 
registries serving the tertiary university teaching hospitals at 
Ibadan and Ile-Ife. The main cancer registry at Ibadan is the 
only population-based registry in Nigeria, serving a popula-
tion of 1.22 million (1991 census) or more (2001 census) with 
a defined area of 70 square kilometers in Ibadan, Oyo state, 
SW Nigeria.59 Data for UCH Ibadan is regularly obtained from 
all the hospitals and health facilities (public, mission, and 
private) in the local government counties subserving the reg-
istry.59 In addition, the UCH is the National Headquarters for 
Cancer Registries in Nigeria, which coordinates the training 
programs and establishment of other zonal registries through-
out the country. In this respect, data from this registry could 
be more precise, better managed, and its specific population 
boundaries better defined to enhance its apparent recording 
of higher incidence rates.  Traditionally, UCH Ibadan, which 
is the nation’s leading tertiary health institution, remains the 
last referral option for most Nigerians, irrespective of their 
regions of domicile, and this may have contributed to the 
higher than average incidence of prostate cancer recorded 
by its registry. On the other hand, the urbanized nature of 
Ibadan, its environs, and its outer reaches, like Ile-Ife, could 
have been ideal for an increased culture of cancer screening, 
and health care access provided by the tertiary hospitals in 
the SW zone of Nigeria. The highly skewed incidence rates 
of disease in this region could thus be explained, at least in 
part, by its early adoption of the PSA test, and the level of 
health awareness of its population.
Prostate cancer stage of T3, C or greater, recorded for 
the vast majority of patients from one of the tertiary hos-
pitals in the SE zone of Nigeria, has been attributed to the 
late presentation of prostate cancer among these patients.60 
The greater than 80% presentation of advanced disease in 
these patients may not have appropriately represented the 
demographic characteristics of the disease in this zone. One 
reason for the poor demographic representation of data in this 
zone was the very low number of cases seen (n = 27) over 
a 5 year period, indicating that these were hospital-referred 
symptomatic cases at the time of presentation. Again, the 
presence of a major tertiary hospital (ie, University of Nigeria 
Teaching Hospital, Enugu) within 200 km of the source of 
these data suggests that case loads might have been lifted off 
the smaller registries. Whereas a lower percentage (19.3%) of 
advanced disease was reported in a SS zonal study, a much 
worse staging of T4 (62.1%) was reported for patients in this 
zone at the time of presentation to hospital. Although there 
were only two comprehensive zonal representative reports 
available on TNM staging of prostate cancer in Nigeria, the 
uncovering of advanced disease here does not deviate from 
countrywide reports of the advanced stages of disease seen 
in hospitals.21,43 The staging of close to one third or more of 
tumors in the southern zones, such as those extending through 
the capsule (stage C) using Whitmore-Jewett criteria agrees 
closely with the TNM staging scheme reported earlier. Tumor 
staging in the geopolitical zones by the Whitmore-Jewett 
criteria also revealed that more than half of the patients had 
tumors that had spread to other organs (stage D). This also 
closely resembled the tumor grading found in the SS zone 
by the TNM scheme. To estimate the destructive potential 
and ultimate prognosis of the disease, pathologists from the 
SS, NC, and NW zones used the histologic scoring system 
to show the profile of surgical and biopsy specimens.25,31,61 
Based on histologic scoring of NC and NW specimens, 20% 
and 49%, respectively, were considered to be high-grade or 
poorly differentiated. This suggests that these patients had an Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
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increased tumor burden that was associated with a higher risk 
of metastatic disease, an increased chance of post-treatment 
failure, and a worse overall prognosis.62–64 Using this prostatic 
adenocarcinoma classification scheme, between 13% and 
73% of tumor specimens were considered moderately dif-
ferentiated or generally low-grade tumors. The 73% outlier 
value reported from the NW1 derives from the summing of 
well and moderately differentiated carcinoma as a group.25 
Furthermore, 38%–67% of tumor specimens analyzed from 
these zones were well differentiated or low grade tumors. 
Based on the Gleason grading system, regarded as the “gold 
standard” for classifying prostatic adenocarcinoma,65 an aver-
age of one third of the northern zonal cases were high grade, 
corroborating the TNM and the Whitmore-Jewett staging 
reported earlier from the southern zones.
Evaluation of the significance of race on prostate cancer 
presentation and progression revealed a correspondence 
between the 52% rate of stage D disease found in African-
American men66 and the observation that more than 50% 
of patients in this study presented with the disease in the 
southern zones of Nigeria. The 52% rate of stage D disease 
observed in African-American men was far higher than the 
26% rate observed in Caucasians with access to the same 
military health care system.66 The biological difference that 
could account for the different stages of prostate cancer 
among African-Americans and Caucasians provided with 
the same standard of health care is yet to be elucidated.53 
In addition, African-American men have been reported to 
present with a higher incidence (16.1%) of advanced dis-
ease or distant metastasis (from combined categories T3/
T4, N1, or M1) than   Caucasians (3.8%).53 More disturbing 
is the observation of a worse scenario in which 62.1% of 
Nigerian men from the SS zone presented with T4 disease. 
On the Gleason grading system, a comparable number of 
African-American men (35%) and Nigerian men (30%) 
from the northern geopolitical zones had high grade tumor 
scores when viewed against data for Caucasians (25%).53 The 
reasons for presentation of advanced disease by most inner 
city African-Americans and most likely Nigerians, in contrast 
with Caucasians, could be attributed to rare screening or 
hospital visitation by the former, except during symptomatic 
and aggressive disease.67
Limitations of this study include the dominance of its 
data by hospital-based registry reports and its substantially 
retrospective nature, both leading to an underestimation of 
the definite number of prostate cancer cases in the studied 
populations. The reasons for these low cases could be asso-
ciated with exclusion of latent and symptom-free subjects 
from hospital reports, and the incomplete documentation 
and retrieval systems used by most of the registries. Another 
limitation of this study is the discordant research strategy 
and data presentation, causing overlap and divergence of 
the study periods, leading to great difficulty in harmoniz-
ing the data. Finally, most of the data presented are limited 
by the exclusion of specific histologic subtyping of cases, 
which would have had significant prognostic and therapeutic 
implications.
Conclusion and recommendations
This study suggests that the incidence of prostate cancer 
among Nigerian men is higher at a younger age than in 
Western   countries. Reasons for such early disease occur-
rence may include behavior, biology, or both. This early 
age of disease prevalence in Nigeria weakens the rationale 
for use of hospital-based registry data to demonstrate the 
incidence of prostate cancer in Nigeria. The finding of 
advanced disease in more than one-third of hospital-based 
cases seen in all the zones, regardless of the tumor grading 
scheme used, is an indication that the reported cases are 
mostly for symptomatic patients. This justifies funding of 
quality, controlled, population-based screening programs in 
all the regions. The data also suggest the need to investigate 
closeness of incidence of disease in the Nigerian and African-
American populations as opposed to Caucasian populations. 
This is particularly relevant, given that our study population 
accounted for a highly significant proportion of the African 
diaspora, indicating that both populations may harbor similar 
inherited genetic predispositions that trigger alterations asso-
ciated with increased risk of prostate cancer. Considering 
the inconsistent pattern of reported findings for each study, 
we recommend the formation of a national study group on 
prostate cancer, which would formulate national guidelines 
for a research strategy and presentation of study protocols. 
Such an arrangement would enhance the harmonization of 
these diverse investigations into coherent demographic and 
health reports of prostate cancer. We also recommend the 
formation of collaborative study programs on population-
based screening of Nigerian men and African-American 
men, in addition to examining genetic variants predisposing 
to prostate cancer that may be common in these populations. 
Elucidation of such common genetic variants may unmask 
common pathways in prostate carcinogenesis and reveal a 
universal etiology of prostate cancer. Moreover, identifica-
tion of specific histologic subtypes of cancer in pathology 
reports may lead to significant prognosis of the cases and 
enable development of suitable therapeutic interventions.Clinical Epidemiology 2012:4 submit your manuscript | www.dovepress.com
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